JPMorgan raises Replimune target to $21; keeps Overweight
JPMorgan raised its Replimune price target to $21 from $20 and maintained an Overweight rating, citing commentary on PD-1 refractory melanoma and a role for Tudriqev.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.